VivoSim Labs, Inc. (NASDAQ:VIVS) Sees Significant Decline in Short Interest

VivoSim Labs, Inc. (NASDAQ:VIVS) was the recipient of a large decrease in short interest during the month of February. As of February 13th, there was short interest totaling 87,870 shares, a decrease of 88.7% from the January 29th total of 774,911 shares. Based on an average daily volume of 394,842 shares, the short-interest ratio is presently 0.2 days. Currently, 3.5% of the company’s stock are sold short. Currently, 3.5% of the company’s stock are sold short. Based on an average daily volume of 394,842 shares, the short-interest ratio is presently 0.2 days.

Hedge Funds Weigh In On VivoSim Labs

An institutional investor recently bought a new position in VivoSim Labs stock. Two Sigma Investments LP bought a new position in VivoSim Labs, Inc. (NASDAQ:VIVS) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned about 0.89% of VivoSim Labs as of its most recent SEC filing. Institutional investors and hedge funds own 8.23% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of VivoSim Labs in a research note on Wednesday, January 21st. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

VivoSim Labs Trading Up 5.7%

Shares of NASDAQ VIVS opened at $2.05 on Thursday. The company has a 50 day simple moving average of $2.03 and a two-hundred day simple moving average of $2.37. The stock has a market cap of $5.35 million, a price-to-earnings ratio of -0.97 and a beta of 1.21. VivoSim Labs has a 12 month low of $1.41 and a 12 month high of $18.60.

VivoSim Labs (NASDAQ:VIVS) last released its quarterly earnings data on Wednesday, February 11th. The company reported ($1.03) earnings per share for the quarter. The business had revenue of $0.03 million during the quarter. VivoSim Labs had a negative return on equity of 15.51% and a negative net margin of 861.27%.

VivoSim Labs Company Profile

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.